AMIRTHATHI NEI FOR SURAPEENISAM

PHASE II NON RANDOMIZED CLINICAL STUDY ON SURAPEENISAM (SINUSITIS ) WITH THE EVALUATION OF THE SIDDHA TRIAL DRUG AMIRTHATHI NEI(INTERNAL) ELUMICHANKAI ENNAI(EXTERNAL) IN CHILDREN

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036354

Enrollment

Registered

2021-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J019- Acute sinusitis, unspecified

Interventions

Intervention1: Amirthathi nei(INTERNAL) ELUMICHANKAI ENNAI (EXTERNAL): Amirthathi nei 5-10 ml of bd for 21 days. External application of Elumichankai ennai oil bath for weekly twice for 21 days Contr

Eligibility

Inclusion criteria

Inclusion criteria: Nasal congestion Headache Recurrent sneezing Running nose Pain and tenderness over PNS

Exclusion criteria

Exclusion criteria: Vasomotor rhinitis Ophthalmic headache Migraine Otitis media

Design outcomes

Primary

Measure	Time frame
Reduction in clinical symptoms Timepoint: 21 days	—

Secondary

Measure	Time frame
It is assessed by comparing the safety parameters before and after treatmentTimepoint: 21 days	—

Countries

India

Contacts

Public ContactDr Bakkialakshmi R

Government Siddha Medical College

drvranimd@yahoo.com6369113461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026